These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21869701)

  • 1. Central nervous system drug development, basic, and clinical research: thinking outside the box.
    Klein DF; Glick ID; Shader RI
    J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular imaging as a de-risking tool: coming into focus?
    Mullard A
    Nat Rev Drug Discov; 2013 Apr; 12(4):251-2. PubMed ID: 23535924
    [No Abstract]   [Full Text] [Related]  

  • 3. An introduction to adaptive designs and adaptation in CNS trials.
    Dragalin V
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):153-8. PubMed ID: 20888739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 5. Special issue on CNS experimental medicine.
    Dawson GR; Dourish CT; Goodwin GM
    J Psychopharmacol; 2011 Sep; 25(9):1145-7. PubMed ID: 21994313
    [No Abstract]   [Full Text] [Related]  

  • 6. An audience with...Luca Santarelli. Interview by Alexandra Flemming.
    Santarelli L
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274461
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical trials in CNS--SMi's eighth annual conference.
    Kirk R
    IDrugs; 2010 Feb; 13(2):66-9. PubMed ID: 20127552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
    Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
    Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Trials in CNS--SMi's Seventh Annual Conference. 25-26 November 2008, London, UK.
    Sherwood D
    IDrugs; 2009 Feb; 12(2):84-6. PubMed ID: 19204879
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Trials in CNS - SMi conference.
    Filson S
    IDrugs; 2007 Jan; 10(1):23-5. PubMed ID: 17187309
    [No Abstract]   [Full Text] [Related]  

  • 12. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural modifications that alter the P-glycoprotein efflux properties of compounds.
    Hitchcock SA
    J Med Chem; 2012 Jun; 55(11):4877-95. PubMed ID: 22506484
    [No Abstract]   [Full Text] [Related]  

  • 14. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches.
    Thoenen H; Sendtner M
    Nat Neurosci; 2002 Nov; 5 Suppl():1046-50. PubMed ID: 12403983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for fMRI in optimizing CNS drug development.
    Borsook D; Becerra L; Hargreaves R
    Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Neuroscience--Seventh Biennial FENS Forum.
    Hannan AJ
    IDrugs; 2010 Sep; 13(9):607-9. PubMed ID: 20799140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peter Corr outlines Pfizer's approach to innovation, maximizing capabilities and delivering essential medicine. Interview by Steve Carney.
    Corr PB
    Drug Discov Today; 2005 Aug; 10(15):1017-20. PubMed ID: 16055016
    [No Abstract]   [Full Text] [Related]  

  • 19. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
    Al-Shamahi A; Kirkham K; Hookes L
    IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of neuroprotective compounds in the pharmaceutical industry: where are we, and where are we going?
    Santilli N
    Prog Brain Res; 2002; 135():497-507. PubMed ID: 12143368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.